Searched for
DRUGMAKER PFIZER
Pfizer CFO Dave Denton to leave company in AugustPfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure r...- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- Eli Lilly brings monthly Alzheimer's therapy donanemab to India at ₹91,688 per vialEli Lilly is making Alzheimer's a major focus for its future innovations. The company is also expanding its specialty medicine offerings in...
- US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...
- US Stocks | Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats upKailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range....
- Pfizer in diabetes drug deal with Sciwind BiosciencesPfizer has partnered with Sciwind Biosciences for a new type 2 diabetes drug. The deal could be worth up to 495 million dollars. This drug,...
- Pfizer agrees to lower prescription drug costs for Medicaid in a deal with TrumpPfizer agreed to lower drug costs and invest $70 billion in U.S. manufacturing following a deal with the Trump administration. The drugmake...
- Pfizer says COVID-19 vaccine will cost $110-$130 per doseThe drugmaker said it expects that people with private health insurance or coverage through public programmes like Medicare or Medicaid wil...
- Pfizer to maintain drug supply to Russia, stops new clinical trialsThe Russian invasion has left drugmakers scrambling to find ways for patients enrolled in clinical trials in Ukraine to receive their medic...
- Pfizer joins Beam Therapeutics to develop rare disease therapiesBeam will receive $300 million in upfront payment and lead research activities till three new therapy targets are selected for development ...
- Pfizer applies for COVID-19 vaccine approval in JapanDrugmaker Pfizer Inc said on Friday it had applied for approval in Japan for its COVID-19 vaccine, which is already being administered in t...
- Pfizer has not discussed AstraZeneca bid with regulators: European Union's AlmuniaPfizer is seeking to acquire Britain's second-biggest drugmaker and may have to sweeten its offer after AstraZeneca rejected the bid.
- Pfizer says keen to engage with AstraZeneca boardAstraZeneca has rejected a $106 billion bid from Pfizer but the US group is widely expected to return with a higher offer later this week.
- Pfizer to appeal India decision to revoke cancer drug patentPfizer Ltd, the India unit of US drugmaker Pfizer Inc, will challenge the country's patent office for revoking a patent for its cancer drug...
- Orchid Chemicals settles case with Pfizer Inc; stock downHyderabad-based Orchid Chemicals has reached an out-of-court settlement with world’s largest drugmaker Pfizer Inc to sell a low-cost versio...
- Orchid Chemicals settles case with Pfizer IncOrchid Chemicals has reached an out-of-court settlement with world’s largest drugmaker Pfizer Inc to sell a low-cost version of the America...
- Pfizer awards bonuses to executives for Wyeth dealChief Financial Officer Frank D'Amelio will receive a $1.2 million award and Ian Read, group president of Pfizer's biopharmaceutical busine...
- Reports: Pfizer, Wyeth said to be close to dealPfizer and Wyeth are closing in on a deal worth $68 billion that could be announced before the markets open Monday.
- Pfizer to spend 300 mn dlr on R&D in KoreaPfizer Inc, the world's biggest drugmaker, will spend $300 million on research and development in South Korea by 2012, in what the governme...
- Pfizer to spend 300 mn dlr on R&D in KoreaPfizer Inc, the world's biggest drugmaker, will spend $300 million on research and development in South Korea by 2012, in what the governme...
Load More
